| scholarly article | Q13442814 |
| P2093 | author name string | Michael Weinblatt | |
| Dalei Chen | |||
| Michael Schiff | |||
| Joel Kremer | |||
| Jean-Claude Becker | |||
| Tracy Li | |||
| Allan Goldman | |||
| Michael Luggen | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. | Q33648354 | ||
| Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate | Q34547988 | ||
| Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial | Q34559671 | ||
| Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion | Q56904375 | ||
| The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis | Q68109843 | ||
| Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig | Q79290408 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 228-234 | |
| P577 | publication date | 2006-08-25 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial | |
| P478 | volume | 66 |
| Q37428436 | A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview |
| Q54422386 | A revolutionary therapeutic approach for psoriasis: bispecific biological agents. |
| Q62633597 | ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate |
| Q24240131 | Abatacept for rheumatoid arthritis |
| Q37672814 | Abatacept for the treatment of rheumatoid arthritis: A review |
| Q37307846 | Abatacept in difficult-to-treat juvenile idiopathic arthritis. |
| Q41905727 | Abatacept in the treatment of rheumatoid arthritis |
| Q37533319 | Abatacept therapy and safety management |
| Q38006176 | Abatacept therapy and safety management |
| Q34588972 | Abatacept treatment for rheumatoid arthritis |
| Q37015967 | Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis |
| Q36967284 | Abatacept: a novel treatment for rheumatoid arthritis |
| Q38116472 | Abatacept: a review of its use in the management of rheumatoid arthritis |
| Q34449851 | Abatacept: the evidence for its place in the treatment of rheumatoid arthritis |
| Q37032656 | Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis |
| Q38431512 | Advances in use of immunomodulatory agents--a rheumatology perspective |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q38238948 | Adverse reactions to biologic agents and their medical management. |
| Q37607078 | Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis |
| Q26997311 | Anti-TNF therapy: past, present and future |
| Q38248092 | Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? |
| Q43451114 | Assessing infection risk with biologic agents in RA: methodological challenges |
| Q33819684 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry |
| Q38720420 | Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery. |
| Q38748557 | Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases |
| Q38192553 | Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q37390458 | Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q33898103 | Biologics and heart failure in rheumatoid arthritis: are we any wiser? |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q38255765 | Blockade of co-stimulation in chronic inflammatory diseases |
| Q43473208 | Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression. |
| Q26824580 | Cellular targeting in autoimmunity |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q91650508 | Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis |
| Q36892770 | Clinical pharmacokinetics and use of infliximab |
| Q36762882 | Clinical targeting of the TNF and TNFR superfamilies |
| Q53811206 | Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. |
| Q46087661 | Combination of biologics : where do we stand? |
| Q50700806 | Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. |
| Q38170177 | Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis |
| Q91248962 | Current and future perspectives in the management of juvenile idiopathic arthritis |
| Q30009098 | Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases |
| Q36667805 | Drug Insight: abatacept for the treatment of rheumatoid arthritis |
| Q36194054 | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| Q37997559 | Dual targeting strategies with bispecific antibodies |
| Q92607395 | Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study |
| Q58732393 | Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review |
| Q57547667 | Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q57956128 | Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis |
| Q36174720 | Estrogen accelerates the resolution of inflammation in macrophagic cells |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q38539811 | Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies |
| Q91973878 | Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases |
| Q38027919 | Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine. |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q39264020 | Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. |
| Q37663873 | Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy |
| Q37258347 | Limits of add-on trials: antirheumatic drugs |
| Q47662522 | Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. |
| Q30811550 | Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment |
| Q37404886 | Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment |
| Q40238572 | Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2 |
| Q37401259 | Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept |
| Q58583955 | New and emerging concepts in the use of denosumab for the treatment of osteoporosis |
| Q38057370 | New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment. |
| Q36849874 | New therapies for treatment of rheumatoid arthritis |
| Q37682875 | Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity |
| Q37388213 | Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis |
| Q43759995 | Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples |
| Q38259809 | Personalized medicine in rheumatoid arthritis: is the glass half full or half empty? |
| Q37781913 | Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets |
| Q59137786 | Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate |
| Q34153073 | Rationale of using different biological therapies in rheumatoid arthritis |
| Q38522837 | Regulating against the dysregulation: new treatment options in autoinflammation |
| Q33809045 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics |
| Q41362251 | Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab |
| Q37326017 | Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial |
| Q37944433 | Safety of biologic therapy in rheumatoid arthritis |
| Q47755721 | Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. |
| Q45182196 | Screening investigations during intensified immunosuppression in children and adolescents. Part 1 |
| Q36536688 | Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade |
| Q48933199 | Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japa |
| Q39302290 | Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis |
| Q92058308 | TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management |
| Q26776492 | TNF biology, pathogenic mechanisms and emerging therapeutic strategies |
| Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
| Q36059373 | The efficacy and safety of abatacept in rheumatoid arthritis. |
| Q38082588 | The problem of choice: current biologic agents and future prospects in RA. |
| Q34984568 | The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials |
| Q37736260 | Therapeutic antibodies for autoimmunity and inflammation |
| Q26849497 | Treatment of juvenile idiopathic arthritis: a revolution in care |
| Q36869567 | Update on abatacept: a selective costimulation modulator for rheumatoid arthritis |
| Q38125240 | Update on the use of abatacept for the treatment of rheumatoid arthritis. |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q83398658 | [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] |
| Q90373577 | [Biologicals and small molecules for rheumatoid arthritis] |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
| Q81814153 | [Recommedations for the use of abatacept in patients with rheumatoid arthritis] |
| Q52902186 | [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)]. |
Search more.